Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDXG 
MiMedx Group Inc (MDXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: MDXG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.2
1 Year Target Price $12.2
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.9% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 994.29M USD | Price to earnings Ratio 31.62 | 1Y Target Price 12.2 |
Price to earnings Ratio 31.62 | 1Y Target Price 12.2 | ||
Volume (30-day avg) 5 | Beta 1.73 | 52 Weeks Range 5.69 - 10.14 | Updated Date 10/24/2025 |
52 Weeks Range 5.69 - 10.14 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When - | Estimate 0.058 | Actual - |
Profitability
Profit Margin 8.84% | Operating Margin (TTM) 12.55% |
Management Effectiveness
Return on Assets (TTM) 10.37% | Return on Equity (TTM) 16.61% |
Valuation
Trailing PE 31.62 | Forward PE 19.53 | Enterprise Value 892399681 | Price to Sales(TTM) 2.73 |
Enterprise Value 892399681 | Price to Sales(TTM) 2.73 | ||
Enterprise Value to Revenue 2.45 | Enterprise Value to EBITDA 16.92 | Shares Outstanding 147959416 | Shares Floating 108772365 |
Shares Outstanding 147959416 | Shares Floating 108772365 | ||
Percent Insiders 1.7 | Percent Institutions 70.93 |
Upturn AI SWOT
MiMedx Group Inc
Company Overview
History and Background
MiMedx Group, Inc. was founded in 2008. It initially focused on developing and marketing regenerative biomaterials derived from human placental tissue. It has evolved through restructuring and addressing compliance matters to refocus on its core wound care and surgical products.
Core Business Areas
- Wound Care: Develops and markets advanced wound care products derived from placental tissues, used for treating chronic non-healing wounds such as diabetic foot ulcers and venous leg ulcers.
- Surgical: Offers surgical biologics utilized in various surgical applications, including sports medicine, orthopedic, spine, and general surgery procedures.
Leadership and Structure
The leadership team includes Joseph H. Capper as Chairman and CEO. The organizational structure is typical of a publicly traded company with executive leadership overseeing functional departments such as sales, marketing, R&D, and finance.
Top Products and Market Share
Key Offerings
- EpiFix: A dehydrated human amnion/chorion membrane (dHACM) allograft used for wound care. EpiFix is a key product. Competitors include Organogenesis (APLX) and Integra LifeSciences (IART). While precise market share data is dynamic and not fully publicly available, it is estimated that MiMedx holds a significant portion of the market in placental-based wound care.
- AmnioFix: Another dHACM allograft product, but is specifically used for surgical applications such as tendon and ligament repair. Competitors include AlloSource and RTI Surgical (RTIX). Revenue for AmnioFix contributes significantly to overall surgical revenue.
Market Dynamics
Industry Overview
The advanced wound care and surgical biologics market is growing due to an aging population, rising incidence of chronic diseases like diabetes, and increasing demand for minimally invasive surgical procedures. The market is competitive and technology-driven.
Positioning
MiMedx is positioned as a leader in placental-derived biomaterials. Its competitive advantages include its proprietary processing techniques, extensive clinical data supporting its products, and established sales and distribution network.
Total Addressable Market (TAM)
The global advanced wound care market is estimated to be worth billions of dollars. MiMedx, with its focus on biologics, aims to capture a substantial portion of the TAM by expanding its product portfolio and market reach.
Upturn SWOT Analysis
Strengths
- Proprietary processing technology
- Extensive clinical data
- Established sales and distribution network
- Strong brand recognition within placental biologics
Weaknesses
- Past accounting irregularities
- Reliance on a limited number of key products
- Potential reimbursement pressures
Opportunities
- Expanding into new therapeutic areas
- Developing new products
- Acquiring complementary technologies
- Increasing market penetration in existing markets
Threats
- Competition from established wound care and surgical companies
- Reimbursement cuts
- Regulatory changes
- Patent expiration of key products
Competitors and Market Share
Key Competitors
- APLX
- IART
- RTIX
Competitive Landscape
MiMedxu2019s advantage lies in its specialization in placental-derived products, giving it a niche compared to larger, more diversified competitors. They must work to secure reimbursement.
Major Acquisitions
HealSource
- Year: 2023
- Acquisition Price (USD millions): 7.5
- Strategic Rationale: Strengthens the companyu2019s wound care sales efforts to support continued growth.
Growth Trajectory and Initiatives
Historical Growth: MiMedx experienced rapid growth in its early years, followed by a period of challenges due to past revenue recognition issues. Recently, it has demonstrated renewed growth.
Future Projections: Analysts predict continued revenue growth driven by expanding product portfolio, increased market penetration, and strategic partnerships.
Recent Initiatives: Recent initiatives include launching new products, expanding its sales force, and pursuing strategic acquisitions.
Summary
MiMedx is a regenerative biomaterials company showing signs of strong growth and a focused strategy on wound care and surgical markets. Its specialization in placental-derived products provides a distinct advantage, though it faces competition from larger players. Addressing past compliance issues and securing favorable reimbursement are crucial for sustained success. Recent acquisitions and product launches point to a positive growth trajectory. The financial performance shows growth in revenue and improvement in net income.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q, 8-K)
- Earnings call transcripts
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market data and analyst estimates are subject to change. Conduct your own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MiMedx Group Inc
Exchange NASDAQ | Headquaters Marietta, GA, United States | ||
IPO Launch date 2007-08-22 | CEO & Director Mr. Joseph H. Capper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 837 | Website https://www.mimedx.com |
Full time employees 837 | Website https://www.mimedx.com | ||
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.